GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) announced a final dividend of ₹57 per equity share for the financial year ended March 31, 2026, as approved by its board of directors at a meeting held on May 13, 2026. The record date for dividend eligibility has been fixed at May 29, 2026. At the current market price of ₹2,420, this translates to a dividend yield of approximately 2.36%.

Dividend Details and Year-on-Year Comparison

The ₹57 per share final dividend represents a 35.7% increase over the ₹42 per share final dividend declared in May 2025. This is a pure final dividend with no interim component announced for FY2026, unlike FY2025 when the company had also paid an interim dividend of ₹12 per share in October 2024, bringing the total FY2025 payout to ₹54 per share. On that combined basis, the FY2026 final dividend alone at ₹57 per share exceeds the full-year FY2025 payout by 5.6%.

Historical Dividend Trend

A review of GLAXO's dividend history over the past six years reveals a broadly rising trajectory, with one notable exception:

Excluding the one-time special dividend component in FY2022, the company's regular payout has grown steadily from ₹30 in FY2021 to ₹57 in FY2026, reflecting improving profitability and a consistent shareholder return policy. The FY2023 and FY2024 payouts were flat at ₹32, making the acceleration seen in FY2025 and FY2026 a notable shift in the distribution trend.

Market Context and Valuation

GLAXO shares were trading at ₹2,420 on May 13, 2026, down ₹28.80 or 1.18% on the day. The stock is currently trading at a 52-week low proximity, having touched a 52-week high of ₹3,515.70 on June 5, 2025 and a 52-week low of ₹2,217.60 on March 30, 2026. At the current price, the stock has corrected approximately 31.1% from its 52-week peak.

The stock's trailing price-to-earnings ratio stands at 40.63x, marginally below the sector PE of 41.25x, suggesting the stock is trading broadly in line with its pharmaceutical sector peers on an earnings basis.

Trading and Delivery Data

On the date of the announcement, GLAXO recorded a trading volume of 40,494 shares with a delivery percentage of 56.26%. A delivery ratio above 50% typically indicates a higher proportion of positional or investor-driven activity relative to intraday trading, suggesting that a meaningful share of participants were holding their positions beyond the session. The stock's daily volatility stands at 1.96%, and its total market capitalisation is approximately ₹40,996.26 Cr.

Company Background

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of the global healthcare major GSK plc and is listed across multiple NSE indices including NIFTY MIDCAP 150, NIFTY 500, NIFTY500 HEALTHCARE, and NIFTY LARGEMIDCAP 250. The company focuses on prescription medicines and vaccines in the Indian market.

Shareholders holding GLAXO equity on or before May 29, 2026 will be eligible to receive the ₹57 per share final dividend, subject to applicable tax deductions as per prevailing income tax regulations.